AU2015316592B2 - Liquid inhalation formulation comprising RPL554 - Google Patents

Liquid inhalation formulation comprising RPL554 Download PDF

Info

Publication number
AU2015316592B2
AU2015316592B2 AU2015316592A AU2015316592A AU2015316592B2 AU 2015316592 B2 AU2015316592 B2 AU 2015316592B2 AU 2015316592 A AU2015316592 A AU 2015316592A AU 2015316592 A AU2015316592 A AU 2015316592A AU 2015316592 B2 AU2015316592 B2 AU 2015316592B2
Authority
AU
Australia
Prior art keywords
rpl554
pharmaceutical composition
liquid pharmaceutical
concentration
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015316592A
Other languages
English (en)
Other versions
AU2015316592A1 (en
Inventor
Edward James FRENCH
Phillip A HAYWOOD
Peter Lionel Spargo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verona Pharma Ltd
Original Assignee
Verona Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1416274.7A external-priority patent/GB201416274D0/en
Priority claimed from GBGB1504662.6A external-priority patent/GB201504662D0/en
Application filed by Verona Pharma Ltd filed Critical Verona Pharma Ltd
Publication of AU2015316592A1 publication Critical patent/AU2015316592A1/en
Priority to AU2018286571A priority Critical patent/AU2018286571B2/en
Application granted granted Critical
Publication of AU2015316592B2 publication Critical patent/AU2015316592B2/en
Priority to AU2020203081A priority patent/AU2020203081B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2015316592A 2014-09-15 2015-09-15 Liquid inhalation formulation comprising RPL554 Active AU2015316592B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018286571A AU2018286571B2 (en) 2014-09-15 2018-12-24 Liquid inhalation formulation comprising RPL554
AU2020203081A AU2020203081B2 (en) 2014-09-15 2020-05-11 Liquid inhalation formulation comprising RPL554

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1416274.7A GB201416274D0 (en) 2014-09-15 2014-09-15 Formulation
GB1416274.7 2014-09-15
GBGB1504662.6A GB201504662D0 (en) 2015-03-19 2015-03-19 Formulation
GB1504662.6 2015-03-19
PCT/GB2015/052668 WO2016042313A1 (en) 2014-09-15 2015-09-15 Liquid inhalation formulation comprising rpl554

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2018286571A Division AU2018286571B2 (en) 2014-09-15 2018-12-24 Liquid inhalation formulation comprising RPL554
AU2020203081A Division AU2020203081B2 (en) 2014-09-15 2020-05-11 Liquid inhalation formulation comprising RPL554

Publications (2)

Publication Number Publication Date
AU2015316592A1 AU2015316592A1 (en) 2017-03-23
AU2015316592B2 true AU2015316592B2 (en) 2020-04-02

Family

ID=54196992

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015316592A Active AU2015316592B2 (en) 2014-09-15 2015-09-15 Liquid inhalation formulation comprising RPL554
AU2018286571A Active AU2018286571B2 (en) 2014-09-15 2018-12-24 Liquid inhalation formulation comprising RPL554
AU2020203081A Active AU2020203081B2 (en) 2014-09-15 2020-05-11 Liquid inhalation formulation comprising RPL554

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018286571A Active AU2018286571B2 (en) 2014-09-15 2018-12-24 Liquid inhalation formulation comprising RPL554
AU2020203081A Active AU2020203081B2 (en) 2014-09-15 2020-05-11 Liquid inhalation formulation comprising RPL554

Country Status (27)

Country Link
US (2) US9956171B2 (enExample)
EP (3) EP3494962B1 (enExample)
JP (2) JP6860477B2 (enExample)
KR (1) KR102379309B1 (enExample)
CN (3) CN110051627A (enExample)
AU (3) AU2015316592B2 (enExample)
CA (1) CA2959943C (enExample)
CY (3) CY1120264T1 (enExample)
DK (3) DK3332767T3 (enExample)
ES (3) ES2670025T3 (enExample)
HK (1) HK1249415B (enExample)
HR (3) HRP20180833T1 (enExample)
HU (3) HUE038433T2 (enExample)
IL (1) IL250895B (enExample)
LT (3) LT3193835T (enExample)
MX (1) MX2017003102A (enExample)
MY (1) MY196072A (enExample)
NO (1) NO3193835T3 (enExample)
PH (1) PH12017500479B1 (enExample)
PL (3) PL3193835T3 (enExample)
PT (3) PT3332767T (enExample)
RS (3) RS62252B1 (enExample)
RU (1) RU2699995C2 (enExample)
SG (1) SG11201701854WA (enExample)
SI (3) SI3494962T1 (enExample)
SM (3) SMT201900340T1 (enExample)
WO (1) WO2016042313A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2773142T3 (es) 2014-05-12 2020-07-09 Verona Pharma Plc Nuevo tratamiento
LT3193835T (lt) * 2014-09-15 2018-06-11 Verona Pharma Plc Skysta inhaliuojama vaisto forma, apimanti rpl554
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
HK1251593A1 (zh) 2015-07-24 2019-02-01 豪夫迈‧罗氏有限公司 Bace1抑制剂肽
GB201613054D0 (en) 2016-07-28 2016-09-14 Verona Pharma Plc New compound and process
GB2578093B (en) 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
GB201911517D0 (en) 2019-08-12 2019-09-25 Verona Pharma Plc Pharmaceutical composition
PL4092025T3 (pl) * 2020-01-15 2024-10-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Kompozycja farmaceutyczna tricyklicznego związku będącego podwójnym inhibitorem pde3/pde4
GB202002786D0 (en) * 2020-02-27 2020-04-15 Verona Pharma Plc Liquid pharmaceutical composition
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
KR20250040090A (ko) * 2022-08-08 2025-03-21 베로나 파마 피엘씨 액상 약제학적 조성물
CA3263546A1 (en) * 2022-08-08 2024-02-15 Verona Pharma Limited ENSIFENTRINE (RPL-554) FOR THE TREATMENT OF MODERATE CHRONIC OBSTRUCTIVE PULMONARY DISEASE
EP4609864A4 (en) * 2022-10-28 2026-02-18 Jiangsu Hengrui Pharmaceuticals Co Ltd PHARMACEUTICAL COMPOSITION CONTAINING AN ISOQUINOLINONE COMPOUND AND RELATED PREPARATION PROCESS
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
CN121620356A (zh) * 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物
WO2025003643A1 (en) * 2023-06-26 2025-01-02 Verona Pharma Plc Particulate composition comprising ensifetrine
CN122121878A (zh) * 2023-09-06 2026-05-29 维罗纳制药有限公司 用于治疗慢性阻塞性肺病（copd）的恩塞芬汀
US20250249006A1 (en) * 2024-02-05 2025-08-07 Verona Pharma Plc Treatment
WO2025168706A1 (en) * 2024-02-07 2025-08-14 Verona Pharma Plc Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease
US20250249008A1 (en) * 2024-02-07 2025-08-07 Verona Pharma Plc Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease
WO2026093383A1 (en) * 2024-10-30 2026-05-07 Verona Pharma Plc Treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014037727A1 (en) * 2012-09-06 2014-03-13 Verona Pharma Plc Carcainium salts

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410222D0 (en) * 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
EP1033991B1 (en) 1997-10-09 2002-04-17 Schering Corporation Mometasone furoate suspensions for nebulization
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
DK1165558T3 (da) 1999-03-31 2004-02-09 Vernalis Ltd Pyrimido[6,1-a]isoquinolin-4-on-derivater
US6630169B1 (en) * 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0122031D0 (en) 2001-09-12 2001-10-31 Pfizer Ltd Use of pde4 inhibitors in a dry powder inhaler
RU2440972C2 (ru) * 2004-12-17 2012-01-27 Сипла Лимитед Кристаллический сульфат левосальбутамола, способ его получения и фармацевтическая композиция, содержащая его
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
CA2803459A1 (en) 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Alkaloid aminoester derivatives and medicinal compositions thereof
SI2603509T1 (sl) 2010-08-09 2014-10-30 Verona Pharma Plc Kristalinična oblika spojine PIRIMIDIO(6,1-A) IZOKINOLIN-4-ENA
EP2717855A4 (en) * 2011-06-07 2014-11-12 Parion Sciences Inc Methods of Treatment
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
EP2647627A1 (en) * 2012-04-02 2013-10-09 Almirall, S.A. Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one.
JP6560986B2 (ja) * 2013-03-15 2019-08-14 ヴェローナ ファーマ ピーエルシー 複合製剤
CN106105056B (zh) * 2014-03-11 2019-07-12 Lg电子株式会社 D2d用户设备在通信系统中发送发现信号的方法和设备
ES2773142T3 (es) 2014-05-12 2020-07-09 Verona Pharma Plc Nuevo tratamiento
LT3193835T (lt) * 2014-09-15 2018-06-11 Verona Pharma Plc Skysta inhaliuojama vaisto forma, apimanti rpl554
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014037727A1 (en) * 2012-09-06 2014-03-13 Verona Pharma Plc Carcainium salts

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C. COMPTON ET AL, PULMONARY PHARMACOLOGY & THERAPEUTICS, (2013-10-01), vol. 26, no. 5, pages 562 - 573. *
FRANCIOSI LUI G ET AL, THE LANCET. RESPIRATORY MEDICINE, NOV 2013, vol. 1, no. 9, pages 714 - 727. *
L. CALZETTA ET AL, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (2013-06-13), vol. 346, no. 3, pages 414 - 423. *

Also Published As

Publication number Publication date
MY196072A (en) 2023-03-13
RS62252B1 (sr) 2021-09-30
BR112017005050A2 (pt) 2018-01-23
NO3193835T3 (enExample) 2018-08-04
PL3494962T3 (pl) 2021-12-06
SI3332767T1 (sl) 2019-07-31
ES2730810T3 (es) 2019-11-12
LT3193835T (lt) 2018-06-11
RS57227B1 (sr) 2018-07-31
KR102379309B1 (ko) 2022-03-28
EP3332767B1 (en) 2019-03-20
MX2017003102A (es) 2017-06-14
AU2020203081B2 (en) 2021-08-05
HRP20191122T1 (hr) 2019-09-20
PT3332767T (pt) 2019-06-27
HRP20180833T1 (hr) 2018-06-29
US9956171B2 (en) 2018-05-01
AU2018286571B2 (en) 2020-04-02
CY1124546T1 (el) 2022-07-22
PH12017500479B1 (en) 2021-07-21
EP3332767A1 (en) 2018-06-13
PT3193835T (pt) 2018-03-27
HK1249415B (en) 2019-11-22
CN106794157B (zh) 2021-03-09
CA2959943A1 (en) 2016-03-24
HUE055527T2 (hu) 2021-12-28
CA2959943C (en) 2022-08-16
EP3193835B1 (en) 2018-03-07
CN110051627A (zh) 2019-07-26
SI3494962T1 (sl) 2021-09-30
WO2016042313A1 (en) 2016-03-24
LT3494962T (lt) 2021-07-26
LT3332767T (lt) 2019-06-25
KR20170054406A (ko) 2017-05-17
RU2699995C2 (ru) 2019-09-12
SMT201800242T1 (it) 2018-07-17
CY1120264T1 (el) 2019-07-10
CY1121698T1 (el) 2020-07-31
NZ767296A (en) 2024-01-26
AU2015316592A1 (en) 2017-03-23
CN106794157A (zh) 2017-05-31
JP2017528479A (ja) 2017-09-28
DK3193835T3 (en) 2018-05-07
CN111249260A (zh) 2020-06-09
NZ729796A (en) 2024-01-26
IL250895A0 (en) 2017-04-30
DK3494962T3 (da) 2021-06-21
EP3494962B1 (en) 2021-05-26
PL3193835T3 (pl) 2018-07-31
AU2018286571A1 (en) 2019-01-24
RU2017108432A3 (enExample) 2019-04-01
SMT201900340T1 (it) 2019-07-11
IL250895B (en) 2019-08-29
CN111249260B (zh) 2023-01-10
US20180369139A1 (en) 2018-12-27
AU2020203081A1 (en) 2020-05-28
PL3332767T3 (pl) 2019-10-31
HUE038433T2 (hu) 2018-10-29
NZ767295A (en) 2024-01-26
US20170239178A1 (en) 2017-08-24
JP2019069978A (ja) 2019-05-09
PT3494962T (pt) 2021-06-22
HUE045303T2 (hu) 2019-12-30
EP3494962A1 (en) 2019-06-12
DK3332767T3 (da) 2019-06-24
PH12017500479A1 (en) 2017-07-31
ES2875584T3 (es) 2021-11-10
EP3193835A1 (en) 2017-07-26
JP6860477B2 (ja) 2021-04-14
RU2017108432A (ru) 2018-10-17
HRP20211035T1 (hr) 2021-09-17
US10945950B2 (en) 2021-03-16
SG11201701854WA (en) 2017-04-27
SMT202100479T1 (it) 2021-09-14
ES2670025T3 (es) 2018-05-29
JP6795574B2 (ja) 2020-12-02
RS58897B1 (sr) 2019-08-30
SI3193835T1 (en) 2018-06-29

Similar Documents

Publication Publication Date Title
AU2020203081B2 (en) Liquid inhalation formulation comprising RPL554
HK1249415A1 (en) Liquid inhalation formulation comprising rpl554
US20220265549A1 (en) Pharmaceutical composition comprising ensifentrine
KR20250047802A (ko) 중등도 만성 폐쇄성 폐질환(copd) 치료를 위한 엔시펜트린(rpl-554)
EA012388B1 (ru) Водные суспензии циклесонида для аэрозольного распыления
KR20220149669A (ko) 엔시펜트린 및 글리코피롤레이트를 포함하는 액상 약제학적 조성물
HK40007474B (en) Liquid inhalation formulation comprising rpl554
HK40007474A (en) Liquid inhalation formulation comprising rpl554
HK1233919B (en) Liquid inhalation formulation comprising rpl554
HK1233919A1 (en) Liquid inhalation formulation comprising rpl554
BR112017005050B1 (pt) Composições farmacêuticas líquidas, nebulizador e usos da composição farmacêutica líquida

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)